Yes there is value in pursuing LDL lowering. Especially in the crowd that cannot tolerate statins. The ongoing CVOT trials for the anti-PCSK9 antibody therapies will further bolster the contribution of LDL to cardiovascular disease, if successful. LDL and HDL are both still regarded as independent contributors to cardiovascular disease.
BearDownAZ